[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536965":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":22,"locations":22,"responsibleParty":23,"collaborators":27,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":22,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":22,"maxAge":22,"enrollmentInfo":38,"targetDuration":22,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":48,"overallStatus":51,"whyStopped":22,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":22},{"fullName":5,"class":6},"VA Sierra Nevada Health Care System","FED",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All participants","OTHER","This will be a single population open label trial evaluating immune response to PCV21 in subjects with immunocompromising conditions or receiving immunosuppressive medications.",[13],"Drug: 21-valent pneumococcal conjugate vaccine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","21-valent pneumococcal conjugate vaccine","FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment",[9],[21],"PCV21",null,{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Amneet Rai","Associate Chief of Pharmacy for Informatics, Education, Health Outcomes, and Research",[28],{"name":29,"class":30},"Merck Sharp & Dohme LLC","INDUSTRY","100536965","phase-4-evaluation-of-pcv21-vaccination-among-ppsv23-experienced-immunocompromised-elderly-veterans-100536965",false,"NCT06271681","Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans","Inclusion Criteria:\n\n* Subject meets the CDC definition of an immunocompromising condition\n\n  o chronic renal failure, congenital or acquired asplenia, generalized malignancy, HIV infection, Hodgkin disease, iatrogenic immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, sickle cell disease or other hemoglobinopathies, and solid organ transplant.\n* Have received at least 1 dose of PPSV23\n\nExclusion Criteria:\n\n* Less than 5 years since last receipt of PPSV23 validated to patient medical record and Immunize Nevada Website\n* Previous administration of PCV20\n* Previous administration of PCV13\n* Previous administration of PCV15\n* Less than 14 days since administration of any COVID19 vaccination\n* Previous history of Invasive Pneumococcal Disease (IPD)\n* Antibiotic treatment within the previous 90 days","ALL",{"count":39,"type":40},45,"ESTIMATED","INTERVENTIONAL",[43],"PHASE4","The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster with of 21-valent pneumococcal conjugate vaccine . Immune response will be assessed by opsonophagocytic assay reactivity.",[46,47],"Pneumococcal Vaccines","Immunosuppression",[49,50],"immunosuppression","pneumococcal vaccines","NOT_YET_RECRUITING","2025-08-08",{"date":54,"type":55},"2025-08-14","ACTUAL",{"date":57,"type":40},"2026-01-01",{"date":59,"type":40},"2027-06-01",{"name":5,"class":6}]